Advertisement
Australia markets closed

  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     

  • AUD/USD

    0.6450
    -0.0001 (-0.01%)
     

  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     

  • OIL

    82.78
    +0.88 (+1.07%)
     

  • GOLD

    2,322.70
    -23.70 (-1.01%)
     

  • Bitcoin AUD

    102,568.02
    -11.89 (-0.01%)
     

  • CMC Crypto 200

    1,391.09
    -23.67 (-1.67%)
     

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

Incannex Healthcare
Updated
Incannex Healthcare
Incannex Healthcare

MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Incannex Contact Information:

Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au

Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637
afactor@edisongroup.com